sec filing

NASDAQ · URGN
UroGen Pharma Ltd.
Healthcare · Biotechnology
$42.31
Up+$0.07 (+0.17%)
Updated Sep 14, 2026, 6:36 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.05B
- P/E ratio
- -6.89
- Dividend yield
- 0.00%
- 52-week range
- $15.86 – $50.81
- Volume
- 687.46K
- Avg. volume
- 1.14M
Price performance
URGN price history
1M range · 19 trading sessions · Daily adjusted prices
URGN closed at $42.31 after 19 trading sessions, down 13.90% for the selected period.
- Last close
- $42.31
- Period change
- -13.90%
- Period low
- $42.24
- Period high
- $50.29
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $43.13 | $43.61 | $41.60 | $42.31 | 687.46K |
| Sep 10, 2026 | $44.25 | $44.4799 | $41.85 | $42.24 | 688.67K |
| Sep 9, 2026 | $43.82 | $47.06 | $43.77 | $45.00 | 1.02M |
| Sep 8, 2026 | $43.24 | $44.7199 | $42.50 | $43.815 | 727.72K |
| Sep 4, 2026 | $44.54 | $45.095 | $43.50 | $44.09 | 779.04K |
| Sep 3, 2026 | $44.37 | $45.63 | $43.45 | $44.88 | 877.8K |
| Sep 2, 2026 | $44.01 | $45.88 | $43.49 | $44.42 | 473.5K |
| Sep 1, 2026 | $42.59 | $43.555 | $42.52 | $43.39 | 584.22K |
| Aug 31, 2026 | $43.17 | $44.86 | $42.00 | $43.09 | 749.05K |
| Aug 28, 2026 | $45.09 | $45.535 | $43.3898 | $43.62 | 580.05K |
| Aug 27, 2026 | $46.13 | $46.51 | $45.285 | $45.50 | 559.82K |
| Aug 26, 2026 | $46.00 | $46.6388 | $45.36 | $45.94 | 620.26K |
| Aug 25, 2026 | $46.65 | $47.17 | $45.67 | $46.36 | 570.16K |
| Aug 24, 2026 | $46.52 | $47.05 | $45.27 | $46.16 | 849.69K |
| Aug 21, 2026 | $47.13 | $47.28 | $45.60 | $46.86 | 755.58K |
| Aug 20, 2026 | $49.71 | $49.71 | $46.20 | $46.80 | 1.12M |
| Aug 19, 2026 | $49.89 | $50.81 | $48.55 | $50.29 | 2.39M |
| Aug 18, 2026 | $48.93 | $49.5599 | $48.41 | $48.92 | 823.74K |
| Aug 17, 2026 | $48.51 | $49.5099 | $48.16 | $49.14 | 1.3M |
Latest URGN news
The latest Smart Investors Daily articles mentioning URGN.
Stock researchResearch & News · News
Loading stock research…

